nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ABCB1—peripheral nervous system neoplasm	0.174	1	CbGaD
Erlotinib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0442	0.092	CbGbCtD
Erlotinib—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.0379	0.079	CbGbCtD
Erlotinib—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.0326	0.0679	CbGbCtD
Erlotinib—UGT1A1—Etoposide—peripheral nervous system neoplasm	0.0314	0.0654	CbGbCtD
Erlotinib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0306	0.0638	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—peripheral nervous system neoplasm	0.0248	0.0516	CbGbCtD
Erlotinib—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0227	0.0474	CbGbCtD
Erlotinib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0219	0.0456	CbGbCtD
Erlotinib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0189	0.0393	CbGbCtD
Erlotinib—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0182	0.0379	CbGbCtD
Erlotinib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0176	0.0366	CbGbCtD
Erlotinib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0173	0.036	CbGbCtD
Erlotinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0159	0.0332	CbGbCtD
Erlotinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0159	0.0332	CbGbCtD
Erlotinib—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0146	0.0303	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0118	0.0245	CbGbCtD
Erlotinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.011	0.023	CbGbCtD
Erlotinib—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0104	0.0218	CbGbCtD
Erlotinib—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.00957	0.0199	CbGbCtD
Erlotinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00954	0.0199	CbGbCtD
Erlotinib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0092	0.0192	CbGbCtD
Erlotinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00887	0.0185	CbGbCtD
Erlotinib—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00712	0.0148	CbGbCtD
Erlotinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0068	0.0142	CbGbCtD
Erlotinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00634	0.0132	CbGbCtD
Erlotinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00623	0.013	CbGbCtD
Erlotinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00425	0.00885	CbGbCtD
Erlotinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00407	0.00849	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.004	0.00834	CbGbCtD
Erlotinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00373	0.00778	CbGbCtD
Erlotinib—Gefitinib—CHEK2—peripheral nervous system neoplasm	0.00346	0.892	CrCbGaD
Erlotinib—LTK—tongue—peripheral nervous system neoplasm	0.00316	0.13	CbGeAlD
Erlotinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00255	0.0053	CbGbCtD
Erlotinib—ULK3—ganglion—peripheral nervous system neoplasm	0.00173	0.0716	CbGeAlD
Erlotinib—ULK3—tongue—peripheral nervous system neoplasm	0.00172	0.0708	CbGeAlD
Erlotinib—TNK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00115	0.0475	CbGeAlD
Erlotinib—SLCO2B1—ganglion—peripheral nervous system neoplasm	0.000934	0.0386	CbGeAlD
Erlotinib—PIP4K2C—trigeminal ganglion—peripheral nervous system neoplasm	0.000892	0.0368	CbGeAlD
Erlotinib—ULK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000852	0.0352	CbGeAlD
Erlotinib—PIP4K2C—parotid gland—peripheral nervous system neoplasm	0.000842	0.0347	CbGeAlD
Erlotinib—ULK3—parotid gland—peripheral nervous system neoplasm	0.000804	0.0332	CbGeAlD
Erlotinib—MKNK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000802	0.0331	CbGeAlD
Erlotinib—SLK—trigeminal ganglion—peripheral nervous system neoplasm	0.000759	0.0314	CbGeAlD
Erlotinib—SLK—parotid gland—peripheral nervous system neoplasm	0.000716	0.0296	CbGeAlD
Erlotinib—STK10—trigeminal ganglion—peripheral nervous system neoplasm	0.00066	0.0273	CbGeAlD
Erlotinib—MAP2K5—trigeminal ganglion—peripheral nervous system neoplasm	0.00059	0.0243	CbGeAlD
Erlotinib—MAP2K5—parotid gland—peripheral nervous system neoplasm	0.000556	0.023	CbGeAlD
Erlotinib—JAK3—cerebellum—peripheral nervous system neoplasm	0.000546	0.0226	CbGeAlD
Erlotinib—MAP2K5—brainstem—peripheral nervous system neoplasm	0.000522	0.0215	CbGeAlD
Erlotinib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000522	0.173	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000522	0.173	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000522	0.173	CbGdCrCtD
Erlotinib—TNK1—cerebellum—peripheral nervous system neoplasm	0.000502	0.0207	CbGeAlD
Erlotinib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000483	0.16	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000483	0.16	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000483	0.16	CbGdCrCtD
Erlotinib—ABL1—trigeminal ganglion—peripheral nervous system neoplasm	0.000455	0.0188	CbGeAlD
Erlotinib—FLT3—cerebellum—peripheral nervous system neoplasm	0.000431	0.0178	CbGeAlD
Erlotinib—ABL1—parotid gland—peripheral nervous system neoplasm	0.000429	0.0177	CbGeAlD
Erlotinib—Gefitinib—ABCB1—peripheral nervous system neoplasm	0.00042	0.108	CrCbGaD
Erlotinib—ABL2—cerebellum—peripheral nervous system neoplasm	0.000411	0.017	CbGeAlD
Erlotinib—ABL1—brainstem—peripheral nervous system neoplasm	0.000403	0.0166	CbGeAlD
Erlotinib—EGFR—cerebellum—peripheral nervous system neoplasm	0.000402	0.0166	CbGeAlD
Erlotinib—PIP4K2C—cerebellum—peripheral nervous system neoplasm	0.000389	0.0161	CbGeAlD
Erlotinib—ULK3—cerebellum—peripheral nervous system neoplasm	0.000372	0.0153	CbGeAlD
Erlotinib—MKNK1—cerebellum—peripheral nervous system neoplasm	0.00035	0.0144	CbGeAlD
Erlotinib—SLK—cerebellum—peripheral nervous system neoplasm	0.000331	0.0137	CbGeAlD
Erlotinib—STK10—cerebellum—peripheral nervous system neoplasm	0.000288	0.0119	CbGeAlD
Erlotinib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000287	0.0118	CbGeAlD
Erlotinib—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000271	0.0112	CbGeAlD
Erlotinib—MAP2K5—cerebellum—peripheral nervous system neoplasm	0.000257	0.0106	CbGeAlD
Erlotinib—CYP1A1—parotid gland—peripheral nervous system neoplasm	0.000257	0.0106	CbGeAlD
Erlotinib—SLCO2B1—cerebellum—peripheral nervous system neoplasm	0.0002	0.00827	CbGeAlD
Erlotinib—ABL1—cerebellum—peripheral nervous system neoplasm	0.000198	0.00819	CbGeAlD
Erlotinib—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000174	0.00718	CbGeAlD
Erlotinib—CYP1B1—cerebellum—peripheral nervous system neoplasm	0.000168	0.00694	CbGeAlD
Erlotinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000141	0.00584	CbGeAlD
Erlotinib—ABCG2—cerebellum—peripheral nervous system neoplasm	0.000125	0.00517	CbGeAlD
Erlotinib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000117	0.000546	CcSEcCtD
Erlotinib—Dermatitis bullous—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000546	CcSEcCtD
Erlotinib—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000117	0.000542	CcSEcCtD
Erlotinib—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000117	0.000542	CcSEcCtD
Erlotinib—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000116	0.00054	CcSEcCtD
Erlotinib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000116	0.00054	CcSEcCtD
Erlotinib—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000116	0.00054	CcSEcCtD
Erlotinib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000115	0.000536	CcSEcCtD
Erlotinib—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000115	0.000536	CcSEcCtD
Erlotinib—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000115	0.000532	CcSEcCtD
Erlotinib—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000532	CcSEcCtD
Erlotinib—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000114	0.000531	CcSEcCtD
Erlotinib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000114	0.000531	CcSEcCtD
Erlotinib—Rash—Topotecan—peripheral nervous system neoplasm	0.000114	0.000531	CcSEcCtD
Erlotinib—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000114	0.000531	CcSEcCtD
Erlotinib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000114	0.00053	CcSEcCtD
Erlotinib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000114	0.000529	CcSEcCtD
Erlotinib—Cough—Etoposide—peripheral nervous system neoplasm	0.000114	0.000529	CcSEcCtD
Erlotinib—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000114	0.000528	CcSEcCtD
Erlotinib—Headache—Topotecan—peripheral nervous system neoplasm	0.000114	0.000528	CcSEcCtD
Erlotinib—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000113	0.000527	CcSEcCtD
Erlotinib—Rash—Tretinoin—peripheral nervous system neoplasm	0.000113	0.000527	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000113	0.000527	CcSEcCtD
Erlotinib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000113	0.000526	CcSEcCtD
Erlotinib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000113	0.000526	CcSEcCtD
Erlotinib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000113	0.000526	CcSEcCtD
Erlotinib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000113	0.000524	CcSEcCtD
Erlotinib—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000524	CcSEcCtD
Erlotinib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000113	0.000524	CcSEcCtD
Erlotinib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000113	0.000524	CcSEcCtD
Erlotinib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000113	0.000524	CcSEcCtD
Erlotinib—Pain—Vincristine—peripheral nervous system neoplasm	0.000112	0.000522	CcSEcCtD
Erlotinib—Constipation—Vincristine—peripheral nervous system neoplasm	0.000112	0.000522	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000522	CcSEcCtD
Erlotinib—Rash—Melphalan—peripheral nervous system neoplasm	0.000112	0.00052	CcSEcCtD
Erlotinib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000112	0.00052	CcSEcCtD
Erlotinib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000111	0.000518	CcSEcCtD
Erlotinib—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000517	CcSEcCtD
Erlotinib—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000111	0.000516	CcSEcCtD
Erlotinib—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000111	0.000514	CcSEcCtD
Erlotinib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000513	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.00011	0.000512	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000508	CcSEcCtD
Erlotinib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.000501	CcSEcCtD
Erlotinib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.000501	CcSEcCtD
Erlotinib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000108	0.0005	CcSEcCtD
Erlotinib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000107	0.000499	CcSEcCtD
Erlotinib—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000499	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000497	CcSEcCtD
Erlotinib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000107	0.000496	CcSEcCtD
Erlotinib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000107	0.000496	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000106	0.000492	CcSEcCtD
Erlotinib—Infection—Etoposide—peripheral nervous system neoplasm	0.000106	0.000491	CcSEcCtD
Erlotinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000105	0.00049	CcSEcCtD
Erlotinib—Nausea—Melphalan—peripheral nervous system neoplasm	0.000105	0.00049	CcSEcCtD
Erlotinib—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000487	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000485	CcSEcCtD
Erlotinib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000104	0.000484	CcSEcCtD
Erlotinib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000104	0.000482	CcSEcCtD
Erlotinib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000104	0.000482	CcSEcCtD
Erlotinib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000104	0.000481	CcSEcCtD
Erlotinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000103	0.00048	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000478	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000478	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000475	CcSEcCtD
Erlotinib—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000101	0.000471	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.00047	CcSEcCtD
Erlotinib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000101	0.000469	CcSEcCtD
Erlotinib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000101	0.000467	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.0001	0.000466	CcSEcCtD
Erlotinib—Gastritis—Doxorubicin—peripheral nervous system neoplasm	9.93e-05	0.000462	CcSEcCtD
Erlotinib—Pain—Cisplatin—peripheral nervous system neoplasm	9.93e-05	0.000461	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	9.9e-05	0.00046	CcSEcCtD
Erlotinib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	9.8e-05	0.000456	CcSEcCtD
Erlotinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	9.78e-05	0.000454	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	9.7e-05	0.000451	CcSEcCtD
Erlotinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	9.64e-05	0.000448	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	9.51e-05	0.000442	CcSEcCtD
Erlotinib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	9.49e-05	0.000441	CcSEcCtD
Erlotinib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	9.48e-05	0.000441	CcSEcCtD
Erlotinib—Asthenia—Vincristine—peripheral nervous system neoplasm	9.42e-05	0.000438	CcSEcCtD
Erlotinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	9.4e-05	0.000437	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	9.35e-05	0.000434	CcSEcCtD
Erlotinib—Infestation—Epirubicin—peripheral nervous system neoplasm	9.35e-05	0.000434	CcSEcCtD
Erlotinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	9.34e-05	0.000434	CcSEcCtD
Erlotinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	9.32e-05	0.000433	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	9.27e-05	0.000431	CcSEcCtD
Erlotinib—Rash—Dactinomycin—peripheral nervous system neoplasm	9.27e-05	0.000431	CcSEcCtD
Erlotinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	9.25e-05	0.00043	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—peripheral nervous system neoplasm	9.19e-05	0.000427	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	9.18e-05	0.000427	CcSEcCtD
Erlotinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	9.18e-05	0.000427	CcSEcCtD
Erlotinib—Fatigue—Etoposide—peripheral nervous system neoplasm	9.17e-05	0.000426	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	9.16e-05	0.000426	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	9.11e-05	0.000424	CcSEcCtD
Erlotinib—Constipation—Etoposide—peripheral nervous system neoplasm	9.1e-05	0.000423	CcSEcCtD
Erlotinib—Pain—Etoposide—peripheral nervous system neoplasm	9.1e-05	0.000423	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	9.09e-05	0.000422	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	9.07e-05	0.000422	CcSEcCtD
Erlotinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	9.01e-05	0.000419	CcSEcCtD
Erlotinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	8.98e-05	0.000418	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	8.84e-05	0.000411	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	8.82e-05	0.00041	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	8.78e-05	0.000408	CcSEcCtD
Erlotinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	8.73e-05	0.000406	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	8.7e-05	0.000404	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	8.7e-05	0.000404	CcSEcCtD
Erlotinib—Dizziness—Vincristine—peripheral nervous system neoplasm	8.68e-05	0.000404	CcSEcCtD
Erlotinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	8.66e-05	0.000403	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	8.65e-05	0.000402	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	8.65e-05	0.000402	CcSEcCtD
Erlotinib—Rash—Alitretinoin—peripheral nervous system neoplasm	8.59e-05	0.000399	CcSEcCtD
Erlotinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	8.58e-05	0.000399	CcSEcCtD
Erlotinib—CYP2D6—cerebellum—peripheral nervous system neoplasm	8.58e-05	0.00354	CbGeAlD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	8.58e-05	0.000399	CcSEcCtD
Erlotinib—Headache—Alitretinoin—peripheral nervous system neoplasm	8.54e-05	0.000397	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	8.5e-05	0.000395	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	8.48e-05	0.000394	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	8.44e-05	0.000392	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	8.43e-05	0.000392	CcSEcCtD
Erlotinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	8.41e-05	0.000391	CcSEcCtD
Erlotinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	8.41e-05	0.000391	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	8.41e-05	0.000391	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	8.39e-05	0.00039	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—peripheral nervous system neoplasm	8.39e-05	0.00039	CcSEcCtD
Erlotinib—Vomiting—Vincristine—peripheral nervous system neoplasm	8.35e-05	0.000388	CcSEcCtD
Erlotinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	8.33e-05	0.000387	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	8.29e-05	0.000385	CcSEcCtD
Erlotinib—Rash—Vincristine—peripheral nervous system neoplasm	8.28e-05	0.000385	CcSEcCtD
Erlotinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	8.27e-05	0.000384	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	8.25e-05	0.000383	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	8.23e-05	0.000382	CcSEcCtD
Erlotinib—Headache—Vincristine—peripheral nervous system neoplasm	8.23e-05	0.000382	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	8.18e-05	0.00038	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	8.16e-05	0.000379	CcSEcCtD
Erlotinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	8.09e-05	0.000376	CcSEcCtD
Erlotinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	7.94e-05	0.000369	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	7.94e-05	0.000369	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	7.84e-05	0.000365	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	7.8e-05	0.000363	CcSEcCtD
Erlotinib—Nausea—Vincristine—peripheral nervous system neoplasm	7.8e-05	0.000362	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	7.77e-05	0.000361	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	7.77e-05	0.000361	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	7.67e-05	0.000356	CcSEcCtD
Erlotinib—Asthenia—Etoposide—peripheral nervous system neoplasm	7.63e-05	0.000355	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	7.63e-05	0.000355	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	7.61e-05	0.000354	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	7.56e-05	0.000352	CcSEcCtD
Erlotinib—Chills—Epirubicin—peripheral nervous system neoplasm	7.53e-05	0.00035	CcSEcCtD
Erlotinib—Pruritus—Etoposide—peripheral nervous system neoplasm	7.53e-05	0.00035	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	7.5e-05	0.000348	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—peripheral nervous system neoplasm	7.42e-05	0.000345	CcSEcCtD
Erlotinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	7.38e-05	0.000343	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	7.35e-05	0.000342	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	7.34e-05	0.000341	CcSEcCtD
Erlotinib—Rash—Cisplatin—peripheral nervous system neoplasm	7.32e-05	0.00034	CcSEcCtD
Erlotinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	7.31e-05	0.00034	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	7.31e-05	0.00034	CcSEcCtD
Erlotinib—Erythema—Epirubicin—peripheral nervous system neoplasm	7.31e-05	0.00034	CcSEcCtD
Erlotinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	7.28e-05	0.000338	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	7.26e-05	0.000337	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—peripheral nervous system neoplasm	7.2e-05	0.000335	CcSEcCtD
Erlotinib—Back pain—Epirubicin—peripheral nervous system neoplasm	7.07e-05	0.000328	CcSEcCtD
Erlotinib—Dizziness—Etoposide—peripheral nervous system neoplasm	7.03e-05	0.000327	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	7e-05	0.000325	CcSEcCtD
Erlotinib—Chills—Doxorubicin—peripheral nervous system neoplasm	6.97e-05	0.000324	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	6.94e-05	0.000322	CcSEcCtD
Erlotinib—Nausea—Cisplatin—peripheral nervous system neoplasm	6.9e-05	0.000321	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	6.86e-05	0.000319	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	6.8e-05	0.000316	CcSEcCtD
Erlotinib—Vomiting—Etoposide—peripheral nervous system neoplasm	6.76e-05	0.000314	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	6.76e-05	0.000314	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—peripheral nervous system neoplasm	6.76e-05	0.000314	CcSEcCtD
Erlotinib—Rash—Etoposide—peripheral nervous system neoplasm	6.71e-05	0.000312	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	6.7e-05	0.000311	CcSEcCtD
Erlotinib—Headache—Etoposide—peripheral nervous system neoplasm	6.66e-05	0.00031	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—peripheral nervous system neoplasm	6.66e-05	0.00031	CcSEcCtD
Erlotinib—Syncope—Epirubicin—peripheral nervous system neoplasm	6.55e-05	0.000304	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—peripheral nervous system neoplasm	6.54e-05	0.000304	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	6.42e-05	0.000298	CcSEcCtD
Erlotinib—Cough—Epirubicin—peripheral nervous system neoplasm	6.38e-05	0.000296	CcSEcCtD
Erlotinib—Nausea—Etoposide—peripheral nervous system neoplasm	6.32e-05	0.000294	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	6.22e-05	0.000289	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—peripheral nervous system neoplasm	6.22e-05	0.000289	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—peripheral nervous system neoplasm	6.22e-05	0.000289	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—peripheral nervous system neoplasm	6.2e-05	0.000288	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	6.18e-05	0.000287	CcSEcCtD
Erlotinib—ABCB1—cerebellum—peripheral nervous system neoplasm	6.17e-05	0.00255	CbGeAlD
Erlotinib—Syncope—Doxorubicin—peripheral nervous system neoplasm	6.06e-05	0.000282	CcSEcCtD
Erlotinib—Oedema—Epirubicin—peripheral nervous system neoplasm	5.96e-05	0.000277	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	5.94e-05	0.000276	CcSEcCtD
Erlotinib—Infection—Epirubicin—peripheral nervous system neoplasm	5.92e-05	0.000275	CcSEcCtD
Erlotinib—Cough—Doxorubicin—peripheral nervous system neoplasm	5.9e-05	0.000274	CcSEcCtD
Erlotinib—Shock—Epirubicin—peripheral nervous system neoplasm	5.87e-05	0.000273	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	5.85e-05	0.000272	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	5.84e-05	0.000271	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000269	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	5.76e-05	0.000267	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	5.76e-05	0.000267	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	5.76e-05	0.000267	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000267	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	5.72e-05	0.000266	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—peripheral nervous system neoplasm	5.68e-05	0.000264	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—peripheral nervous system neoplasm	5.52e-05	0.000256	CcSEcCtD
Erlotinib—Infection—Doxorubicin—peripheral nervous system neoplasm	5.48e-05	0.000255	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	5.43e-05	0.000252	CcSEcCtD
Erlotinib—Shock—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.000252	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	5.41e-05	0.000251	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	5.4e-05	0.000251	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—peripheral nervous system neoplasm	5.39e-05	0.000251	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000249	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	5.32e-05	0.000247	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	5.26e-05	0.000244	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	5.25e-05	0.000244	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	5.18e-05	0.000241	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	5.15e-05	0.000239	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.000239	CcSEcCtD
Erlotinib—Pain—Epirubicin—peripheral nervous system neoplasm	5.1e-05	0.000237	CcSEcCtD
Erlotinib—Constipation—Epirubicin—peripheral nervous system neoplasm	5.1e-05	0.000237	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	5.03e-05	0.000234	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	4.99e-05	0.000232	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	4.92e-05	0.000229	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	4.88e-05	0.000227	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	4.86e-05	0.000226	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	4.8e-05	0.000223	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.76e-05	0.000221	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	4.76e-05	0.000221	CcSEcCtD
Erlotinib—Pain—Doxorubicin—peripheral nervous system neoplasm	4.72e-05	0.000219	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	4.72e-05	0.000219	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	4.71e-05	0.000219	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	4.71e-05	0.000219	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	4.51e-05	0.00021	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	4.36e-05	0.000203	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	4.36e-05	0.000203	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	4.28e-05	0.000199	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000196	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	4.08e-05	0.00019	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000184	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.94e-05	0.000183	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.9e-05	0.000181	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.79e-05	0.000176	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.77e-05	0.000175	CcSEcCtD
Erlotinib—Rash—Epirubicin—peripheral nervous system neoplasm	3.76e-05	0.000175	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.76e-05	0.000175	CcSEcCtD
Erlotinib—Headache—Epirubicin—peripheral nervous system neoplasm	3.74e-05	0.000174	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.65e-05	0.00017	CcSEcCtD
Erlotinib—Nausea—Epirubicin—peripheral nervous system neoplasm	3.54e-05	0.000165	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.51e-05	0.000163	CcSEcCtD
Erlotinib—Rash—Doxorubicin—peripheral nervous system neoplasm	3.48e-05	0.000162	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.48e-05	0.000162	CcSEcCtD
Erlotinib—Headache—Doxorubicin—peripheral nervous system neoplasm	3.46e-05	0.000161	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	3.28e-05	0.000152	CcSEcCtD
Erlotinib—EGFR—Focal Adhesion—HRAS—peripheral nervous system neoplasm	1.95e-05	0.000195	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	1.94e-05	0.000195	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—AKT1—peripheral nervous system neoplasm	1.94e-05	0.000194	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	1.93e-05	0.000193	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—NRAS—peripheral nervous system neoplasm	1.92e-05	0.000192	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KNG1—peripheral nervous system neoplasm	1.92e-05	0.000192	CbGpPWpGaD
Erlotinib—JAK3—Immune System—ERBB2—peripheral nervous system neoplasm	1.92e-05	0.000192	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.91e-05	0.000191	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.91e-05	0.000191	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—HRAS—peripheral nervous system neoplasm	1.91e-05	0.000191	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	1.91e-05	0.000191	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—ERBB2—peripheral nervous system neoplasm	1.91e-05	0.000191	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.9e-05	0.000191	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.9e-05	0.00019	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GNS—peripheral nervous system neoplasm	1.9e-05	0.00019	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IFNB1—peripheral nervous system neoplasm	1.88e-05	0.000189	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ENO2—peripheral nervous system neoplasm	1.87e-05	0.000187	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	1.85e-05	0.000186	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.84e-05	0.000184	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	1.83e-05	0.000183	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PTPN11—peripheral nervous system neoplasm	1.82e-05	0.000182	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	1.82e-05	0.000182	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	1.82e-05	0.000182	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—AKT1—peripheral nervous system neoplasm	1.82e-05	0.000182	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NME1—peripheral nervous system neoplasm	1.82e-05	0.000182	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	1.8e-05	0.000181	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.8e-05	0.000181	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—AKT1—peripheral nervous system neoplasm	1.8e-05	0.00018	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	1.79e-05	0.000179	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NRAS—peripheral nervous system neoplasm	1.79e-05	0.000179	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	1.78e-05	0.000178	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.76e-05	0.000177	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.76e-05	0.000176	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.76e-05	0.000176	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—COX2—peripheral nervous system neoplasm	1.75e-05	0.000175	CbGpPWpGaD
Erlotinib—EGFR—Disease—SLC2A1—peripheral nervous system neoplasm	1.75e-05	0.000175	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	1.75e-05	0.000175	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	1.74e-05	0.000174	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—NRAS—peripheral nervous system neoplasm	1.74e-05	0.000174	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GNS—peripheral nervous system neoplasm	1.73e-05	0.000173	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000172	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.71e-05	0.000171	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HGF—peripheral nervous system neoplasm	1.7e-05	0.00017	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	1.7e-05	0.00017	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—BCHE—peripheral nervous system neoplasm	1.69e-05	0.000169	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—AKT1—peripheral nervous system neoplasm	1.68e-05	0.000169	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.68e-05	0.000169	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—GNAS—peripheral nervous system neoplasm	1.68e-05	0.000168	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.67e-05	0.000168	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.67e-05	0.000167	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	1.67e-05	0.000167	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MYC—peripheral nervous system neoplasm	1.66e-05	0.000166	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NME1—peripheral nervous system neoplasm	1.66e-05	0.000166	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.64e-05	0.000164	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—ERBB2—peripheral nervous system neoplasm	1.63e-05	0.000163	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.61e-05	0.000162	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	1.61e-05	0.000161	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	1.61e-05	0.000161	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HGF—peripheral nervous system neoplasm	1.6e-05	0.00016	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.6e-05	0.00016	CbGpPWpGaD
Erlotinib—ALB—Metabolism—COX2—peripheral nervous system neoplasm	1.6e-05	0.00016	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.6e-05	0.00016	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—TH—peripheral nervous system neoplasm	1.59e-05	0.000159	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—MYC—peripheral nervous system neoplasm	1.59e-05	0.000159	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.58e-05	0.000158	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—BCHE—peripheral nervous system neoplasm	1.58e-05	0.000158	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.57e-05	0.000157	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	1.52e-05	0.000152	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.51e-05	0.000151	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.49e-05	0.000149	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—HRAS—peripheral nervous system neoplasm	1.49e-05	0.000149	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TH—peripheral nervous system neoplasm	1.48e-05	0.000149	CbGpPWpGaD
Erlotinib—JAK3—Immune System—NRAS—peripheral nervous system neoplasm	1.46e-05	0.000146	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HGF—peripheral nervous system neoplasm	1.45e-05	0.000146	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.45e-05	0.000146	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.45e-05	0.000145	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—NRAS—peripheral nervous system neoplasm	1.45e-05	0.000145	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.44e-05	0.000144	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	1.44e-05	0.000144	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.43e-05	0.000143	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.42e-05	0.000143	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—NRAS—peripheral nervous system neoplasm	1.42e-05	0.000142	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.4e-05	0.000141	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.4e-05	0.00014	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.39e-05	0.000139	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.38e-05	0.000138	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.37e-05	0.000137	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.37e-05	0.000137	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	1.35e-05	0.000135	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.32e-05	0.000132	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.32e-05	0.000132	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HRAS—peripheral nervous system neoplasm	1.31e-05	0.000131	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GNAS—peripheral nervous system neoplasm	1.3e-05	0.00013	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.29e-05	0.000129	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.28e-05	0.000128	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.28e-05	0.000128	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.27e-05	0.000128	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.27e-05	0.000127	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—HRAS—peripheral nervous system neoplasm	1.27e-05	0.000127	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.25e-05	0.000125	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.25e-05	0.000125	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTPN11—peripheral nervous system neoplasm	1.24e-05	0.000124	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.24e-05	0.000124	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—NRAS—peripheral nervous system neoplasm	1.24e-05	0.000124	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.24e-05	0.000124	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	1.22e-05	0.000122	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GNAS—peripheral nervous system neoplasm	1.21e-05	0.000121	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.21e-05	0.000121	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.19e-05	0.000119	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.17e-05	0.000117	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	1.17e-05	0.000117	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.16e-05	0.000117	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.16e-05	0.000116	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.16e-05	0.000116	CbGpPWpGaD
Erlotinib—MKNK1—Disease—AKT1—peripheral nervous system neoplasm	1.15e-05	0.000115	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ENO2—peripheral nervous system neoplasm	1.15e-05	0.000115	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.14e-05	0.000114	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.13e-05	0.000113	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.12e-05	0.000113	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.12e-05	0.000112	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	1.1e-05	0.00011	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—AKT1—peripheral nervous system neoplasm	1.1e-05	0.00011	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.1e-05	0.00011	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—peripheral nervous system neoplasm	1.09e-05	0.000109	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.08e-05	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.08e-05	0.000108	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—peripheral nervous system neoplasm	1.07e-05	0.000107	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.06e-05	0.000106	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTPN11—peripheral nervous system neoplasm	1.06e-05	0.000106	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	1.05e-05	0.000106	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.05e-05	0.000105	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	1.05e-05	0.000105	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—peripheral nervous system neoplasm	1.04e-05	0.000104	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.03e-05	0.000103	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	1.03e-05	0.000103	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.02e-05	0.000102	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.01e-05	0.000101	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.87e-06	9.88e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.81e-06	9.82e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB2—peripheral nervous system neoplasm	9.81e-06	9.82e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTPN11—peripheral nervous system neoplasm	9.79e-06	9.8e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—BCHE—peripheral nervous system neoplasm	9.72e-06	9.73e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	9.67e-06	9.68e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.56e-06	9.57e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.43e-06	9.44e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—AKT1—peripheral nervous system neoplasm	9.42e-06	9.43e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—peripheral nervous system neoplasm	9.38e-06	9.39e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—AKT1—peripheral nervous system neoplasm	9.37e-06	9.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	9.34e-06	9.35e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.27e-06	9.28e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—AKT1—peripheral nervous system neoplasm	9.19e-06	9.2e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	9.19e-06	9.2e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.17e-06	9.18e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.15e-06	9.15e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TH—peripheral nervous system neoplasm	9.14e-06	9.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—peripheral nervous system neoplasm	9.07e-06	9.08e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	8.96e-06	8.96e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	8.91e-06	8.92e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	8.86e-06	8.87e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	8.78e-06	8.79e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.78e-06	8.79e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	8.66e-06	8.67e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	8.65e-06	8.66e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	8.62e-06	8.63e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.5e-06	8.51e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.45e-06	8.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—peripheral nervous system neoplasm	8.38e-06	8.39e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	8.38e-06	8.38e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TH—peripheral nervous system neoplasm	8.33e-06	8.34e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	8.28e-06	8.29e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.07e-06	8.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.01e-06	8.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—peripheral nervous system neoplasm	8.01e-06	8.02e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	7.89e-06	7.9e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	7.76e-06	7.77e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	7.75e-06	7.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—peripheral nervous system neoplasm	7.74e-06	7.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7.69e-06	7.7e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.68e-06	7.69e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	7.46e-06	7.47e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GNAS—peripheral nervous system neoplasm	7.46e-06	7.47e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.4e-06	7.41e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	7.33e-06	7.34e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	7.32e-06	7.33e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	7.31e-06	7.32e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	7.3e-06	7.3e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.21e-06	7.22e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.16e-06	7.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.07e-06	7.08e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	7.01e-06	7.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.98e-06	6.99e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.98e-06	6.98e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.9e-06	6.9e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	6.88e-06	6.88e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.86e-06	6.87e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	6.84e-06	6.85e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	6.8e-06	6.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.79e-06	6.8e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	6.71e-06	6.72e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	6.67e-06	6.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—peripheral nervous system neoplasm	6.38e-06	6.38e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	6.2e-06	6.2e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.09e-06	6.1e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	5.96e-06	5.96e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.91e-06	5.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—peripheral nervous system neoplasm	5.89e-06	5.89e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.88e-06	5.88e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	5.83e-06	5.83e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	5.66e-06	5.67e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.62e-06	5.63e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	5.61e-06	5.62e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	5.51e-06	5.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—peripheral nervous system neoplasm	5.49e-06	5.49e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	5.46e-06	5.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.42e-06	5.43e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	5.36e-06	5.37e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	5.13e-06	5.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.11e-06	5.11e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.96e-06	4.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.92e-06	4.92e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	4.82e-06	4.83e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	4.78e-06	4.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	4.76e-06	4.76e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	4.67e-06	4.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—peripheral nervous system neoplasm	4.67e-06	4.67e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.56e-06	4.57e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	4.53e-06	4.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.51e-06	4.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	4.5e-06	4.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—peripheral nervous system neoplasm	4.31e-06	4.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.12e-06	4.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—peripheral nervous system neoplasm	4.12e-06	4.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.84e-06	3.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—peripheral nervous system neoplasm	3.8e-06	3.81e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	3.67e-06	3.67e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	3.6e-06	3.61e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—peripheral nervous system neoplasm	3.51e-06	3.51e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—peripheral nervous system neoplasm	3.27e-06	3.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.15e-06	3.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.02e-06	3.02e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.97e-06	2.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.66e-06	2.67e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	2.13e-06	2.13e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—peripheral nervous system neoplasm	2.01e-06	2.02e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	1.85e-06	1.85e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	1.84e-06	1.84e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.61e-06	1.61e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.52e-06	1.52e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.28e-06	1.28e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	9.91e-07	9.92e-06	CbGpPWpGaD
